3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: Implications for Parkinson's disease pathogenesis

Brain Research

Volumn 989, Issue 2, 2003, Pages 205-213

  Burke, William J ^a,b,d   Li, Shu Wen ^c   Williams, Evelyn A ^b   Nonneman, Randal ^a,b   Zahm, Daniel S ^b  

^a S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Saint Louis University   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

3,4 Dihydroxyphenylacetaldehyde; Basal ganglia; Neurodegenerative disorder; Neuron death; Substantia nigra; Ventral tegmental area

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; ALDEHYDE DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING); CELL NUCLEUS ANTIGEN; DOPAMINE DERIVATIVE; DRUG METABOLITE; GLIAL FIBRILLARY ACIDIC PROTEIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN NERVE CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOREACTIVITY; IN VIVO STUDY; INJECTION SITE; MALE; METHYLATION; MORPHOMETRICS; NEUROTOXICITY; NISSL SUBSTANCE; NONHUMAN; OXIDATION; PARKINSON DISEASE; PATHOGENESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

EID: 0141638380     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)03354-7     Document Type: Article

References (42)

1. Bennett D.A., Beckett L.A., Murray A.M., Shannon K.M., Goetz C., Pilgrim D.M., Evans D.A. Prevalence of Parkinsonian signs and associated mortality in a community population of older people. New Engl. J. Med. 334:1996;71-76.
2. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osona M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:2000;1302-1306.
3. Blaschko H. Amine oxidase and amine metabolism. Pharmacol. Rev. 4:1952;415-453.
4. Burke W.J., Chung H.D., Li S.W. Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography. Anal. Biochem. 273:1999;111-116.
5. Burke W.J., Li S.W., Schmitt C.A., Zahm D.S., Chung H.D., Conway A.D., Lampe P., Johnson E.M., Lin T.-S., Kristal B.S., Barg J., Anwar M., Ruggiero D.A. Catecholamine-derived aldehyde neurotoxins. Collins M.A., Storch A. Neurotoxic Factors in Parkinson's Disease. 2000;167-180 Plenum Press, New York.
6. Burke W.J., Li S.W., Zahm D.S., MacArthur H., Kolo L.L., Westfall T.C., Anwar M., Glickstein S.B., Ruggiero D.A. Catecholamine monoamine oxidase A metabolite in adrenergic neurons is cytotoxic in vivo. Brain Res. 891:2001;218-277.
7. W.J. Burke, 3,4-Dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease, Current Drug Targets - CNS Neurological Disorders, in press.
8. Fahn S. Levodopa-induced neurotoxicity. CNS Drugs. 8:1997;376-393.
9. Falkenburger B.H., Barstow K.L., Mintz I.M. Dendrodendritic inhibition through reversal of dopamine transport. Science. 293:2001;2465-2470.
10. Filloux F., Townsend J.J. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastitial injection. Exp. Neurol. 119:1993;79-88.
11. Fornai F., Giorgi F.S., Bassi L.L., Ferrucci M., Alessandri M.G., Corsini G.U. Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat striatum after different kinds of pharmacological treatment. Brain Res. 861:2000;126-134.
12. Giasson B.I., Lee V.M.-Y. A new link between pesticides and Parkinson's disease. Nat. Neurosci. 3:2000;1227-1228.
13. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., Eliezer M. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport. 10:1999;717-721.
14. Hirsch E.C., Facheux B., Damier P., Mouatt-Prigett A., Agid Y. Neuronal vulnerability in Parkinson's disease. J. Neural Transm. 50:1997;79-88.
15. Koller W.C. How accurately can Parkinson's disease be diagnosed. Neurology. 42:(Suppl. 1):1992;6-16.
16. Koller W.C. When does Parkinson's disease begin. Neurology. 42:(Suppl. 4):1992;27-31.
17. Koller W.C. An algorithm for the management of Parkinson's disease. Neurology. 42:(Suppl. 10):1994;1-52.
18. Kristal B.S., Park B.K., Yu B.P. 4-Hydroxyenal is a potent inducer of the mitochondrial permeability transition. J. Biol. Chem. 271:1996;6033-6038.
19. Kristal B.S., Conway A.D., Brown A.M., Jain J.C., Ulluci P.A., Li S.W., Burke W.J. Selective dopaminergic vulnerability: 3, 4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic. Biol. Med. 30:2000;924-931.
20. Kurland L.T. Epidemiology, incidence, geographic distribution and genetic considerations. Fields W.S. Pathogenesis and Treatment of Parkinsonism. 1958;5-49 Charles C. Thomas, Springfield, IL.
21. Lamensdorf I., Eisenhofer G., Harvey-White J., Hayakawa Y., Kirk K., Kopin I.J. Metabolic stress in PC 12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J. Neurosci. Res. 60:2000;552-558.
22. Lamensdorf I., Eisenhofer G., Harvey-White J., Neckustan A., Kirk K., Kopin I.J. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC 12 cells. Brain Res. 868:2000;191-201.
23. Lee F.J.S., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of α-synuclein to dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15:2001;916-926.
24. Li S.W., Spaziano V.T., Burke W.J. Synthesis of a biochemically important aldehyde, 3,4-dihydroxyphenylacetaldehyde. Bioorg. Chem. 26:1998;45-50.
25. Li S.W., Lin T.-S., Minteer S., Burke W.J. 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. Mol. Brain Res. 93:2001;1-7.
26. Osterova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20:2000;6048-6054.
27. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. J. Am. Med. Assoc. 287:2002;1653-1661.
28. Piao Y.S., Wakabayashi K., Hayashi S., Yoshimoto M., Takahashi H. Aggregation of α-synuclein/NACP in neuronal and glial cells in diffuse Lewy body disease: a survey of six patients. Clin. Neuropathol. 19:2002;163-169.
29. Polymeropoulos M.J., Lavendan C., Leroy E., Ide S.E., Dehaja A., Dutra A., Pike B., Root H., Rubenstein J., Stenroos E.S., Chandraskharappa S., Athanassiadou H., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., DiIorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 275:1997;2045-2047.
30. Schapira A.H.V., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:1990;823-827.
31. Storch A., Schwarz J. The dopamine transporter: involvement in selective dopaminergic neurodegeneration. Collins M.A., Storch A. Neurotoxic Factors in Parkinson's Disease. 2000;17-40 Plenum Press, New York.
32. Tan Y., Williams E.A., Lancia A.J., Zahm D.S. On the altered expression of tyrosine hydroxylase and calbindin-D28KD immunoreactivities and viability of neurons in the ventral tegmental area of Tsai following injections of 6-hydroxydopamine in the medial forebrain bundle in the rat. Brain Res. 869:2000;56-68.
33. Trojanowski J.Q., Lee V.M.-Y. Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain. Parkinsonism Rel. Disord. 7:2001;247-251.
34. Turnbull S., Tabner B.J., El-Agnaf O.M., Moore S., Davies Y., Allsop D. Alpha-synuclein implicated Parkinson's disease catalyzed the formation of hydrogen peroxide in vitro. Free Radic. Biol. Med. 30:2001;1163-1170.
35. Volles M.J., Lee S.-J., Rochet J.-C., Shtilerman M.D., Ding T.J., Kessler J.C., Lansbury P.J. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry. 40:2001;7812-7819.
36. Wilson J.X. Antioxidant defense of the brain: a role for astrocytes. Can. J. Physiol. Pharmacol. 75:1997;1149-1163.
37. Winn P., Alderson H.L., Brown V.J., Latimer M.P., Payne K., Thiemann G., Williams E.A., Zahm D.S. Examination of the effects of excitotoxic disconnection lesions of nucleus acucmbens core and shell. Soc. Neurosci. Abstr. 27:2002;422.11.
38. Wolf H.K., Buslei R., Schmidt-Kastner R., Pietsch T., Wiestler D.D., Blumke I. NeuN: a useful marker for diagnostic histopathology. J. Histochem. Cytochem. 44:1996;1167-1171.
39. Wooten F. Agonist vs. levodopa in PD: the thrilla of witha. Neurology. 60:2003;360-362.
40. Xu J., Kao S.-Y., Lee F.J.S., Song W., Jin L.-W., Yankner B.A. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nat. Med. 8:2002;600-606.
41. Zahm D.S., Grosu S., Williams E.A., Qin S., Berod A. Neurons of origin of the neurotensinergic plexus enmeshing the ventral tegmental area in rat: retrograde labeling and in situ hybridization combined. Neuroscience. 104:2001;841-851.
42. Zhou S.S., Gospe S.M. Double labeling of proliferating neurons with anti-Brdu and anti-NeuN: an improved immunohistochemical technique utilizing microwave irradiation. J. Histotechnol. 21:1998;201-204.